Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Down 8.1% in January

Esperion Therapeutics, Inc. (NASDAQ:ESPR) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 31,240,000 shares, a decrease of 8.1% from the January 15th total of 33,980,000 shares. Approximately 16.0% of the company’s shares are short sold. Based on an average trading volume of 6,230,000 shares, the days-to-cover ratio is currently 5.0 days.

Esperion Therapeutics Trading Up 0.5 %

Shares of NASDAQ ESPR opened at $1.87 on Wednesday. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94. The stock has a 50 day moving average price of $2.14 and a 200 day moving average price of $2.11.

Analyst Ratings Changes

A number of research firms recently commented on ESPR. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target for the company. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Esperion Therapeutics has a consensus rating of “Hold” and a consensus price target of $6.75.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ESPR. Wasatch Advisors LP grew its position in shares of Esperion Therapeutics by 4.9% during the 4th quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock worth $53,861,000 after buying an additional 1,136,245 shares in the last quarter. Geode Capital Management LLC grew its holdings in Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after acquiring an additional 171,609 shares in the last quarter. State Street Corp increased its position in Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after purchasing an additional 99,802 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after purchasing an additional 16,100 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock worth $6,862,000 after purchasing an additional 1,020,243 shares during the period. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.